Trial record 11 of 5406 for:    Autoimmune

CHLOROQUINE FOR MAINTENANCE REMISSION OF AUTOIMMUNE HEPATITIS

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
DÉBORA RAQUEL BENEDITA TERRABUIO, University of Sao Paulo General Hospital
ClinicalTrials.gov Identifier:
NCT01980745
First received: September 24, 2013
Last updated: November 4, 2013
Last verified: September 2013
  Purpose

Autoimmune hepatitis is an autoimmune chronic liver disease whose treatment includes the use of immunosuppressive drugs, particularly azathioprine, and corticosteroids. When properly treated, patients have a good survival. One of the major problems related to its treatment is the the high rate of relapses after stopping therapy that has lead to biochemical and histological remissions, close to 80%. Many authors recommend continuous treatment throughout life, resulting in the occurrence of many side effects. Chloroquine is a drug with anti-inflammatory properties already used in the treatment of other extrahepatic autoimmune liver diseases. There are some reports in the literature about its beneficial use in liver diseases such as chronic hepatitis B, and a pilot study in patients with autoimmune hepatitis, in which its use was associated with a 6.49 times lower risk of disease recurrence when compared with patients in whom treatment was discontinued after remission. Our purpose is to investigate, in a double-blind randomized trial with placebo, whether chloroquine prevents the recurrence of AIH in patients with histological remission after discontinuation of conventional treatment and to evaluate the occurrence of side effects.


Condition Intervention Phase
Hepatitis, Autoimmune
Drug: Chloroquine diphosphate 250mg
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL WITH CHLOROQUINE VERSUS PLACEBO FOR MAINTENANCE OF REMISSION OF AUTOIMMUNE HEPATITIS

Resource links provided by NLM:


Further study details as provided by University of Sao Paulo General Hospital:

Primary Outcome Measures:
  • Recurrence of autoimune hepatitis after treatment withdrawal in patients maintained only with chloroquine [ Time Frame: thirty-six months after immunosuppressive treatment withdrawal and initial use of chloroquine ] [ Designated as safety issue: Yes ]
    To evaluate the rate of recurrence of autoimmune hepatitis with histological remission after withdrawal of corticosteroids and immunosuppressive drugs and after introduction of maintenance therapy with chloroquine or placebo. Recurrence is defined by the sustained increase or progressive liver enzymes above twice the upper normal reference value (as defined by the criteria of the International Autoimmune Hepatitis) in at least two different dosages taken with an interval of 15 to 30 days.


Secondary Outcome Measures:
  • Side effects of chloroquine [ Time Frame: thirty-six months after immunosuppressive treatment withdrawal and initial use of chloroquine ] [ Designated as safety issue: Yes ]
    To assess the occurrence of side effects of chloroquine and to evaluate if the use of chloroquine has a cost benefit for maintenance of remission histological, we will investigate hematological, dermatological, opthalmological, neurological, musculoeskeletal and gastrintestinal symptoms. To evaluate the ocular toxicity, patients will undergo ophthalmic evaluation to detect retinal deposits of chloroquine every six months. Other side effects will be assessed in each medical consultation from the speech of patients and clinical examination.If necessary exams will be performed to confirm the diagnosis (eg electromyography in cases of suspected peripheral neuropathy by chloroquine)

  • Side effects of chloroquine [ Time Frame: thirty-six months after immunosuppressive treatment withdrawal and initial use of chloroquine ] [ Designated as safety issue: Yes ]

    To assess the occurrence of side effects of chloroquine and to evaluate if the use of chloroquine has a cost benefit for maintenance of remission histological. We will investigate hematological, dermatological, opthalmological, neurological, musculoeskeletal and gastrintestinal symptoms.

    To evaluate ocular toxicity, patients will undergo ophthalmic evaluation to detect retinal deposits of chloroquine every six months. Other side effects will be assessed in each medical consultation from the talking of patients and clinical examinations. If necessary, other complementary exams will be performed to confirm the diagnosis (for instance, electromyography in cases of suspected peripheral neuropathy by chloroquine).



Estimated Enrollment: 62
Study Start Date: February 2002
Estimated Study Completion Date: November 2014
Estimated Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Chloroquine diphosphate
chloroquine diphosphate 250mg/day
Drug: Chloroquine diphosphate 250mg
Sugar pill (placebo) one pill per day for 1110 days Chloroquine diphosphate 250mg per day for 1110 days
Placebo Comparator: sugar pill
sugar pill
Drug: Placebo

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: - diagnosis of autoimmune hepatitis according to Autoimmune Hepatitis International Group

  • histological remission during treatment with immunosuppressive drugs (Liver biopsy with periportal inflammatory activity less than 2)
  • No evidence of decompensated liver cirrhosis
  • Non-pregnant women and women with no intention to become pregnant
  • Willing to participate in the study

Exclusion Criteria:

  • patients who needed to suspend the drug under six months of the medication because of side effects or the patient's desire
  • cases of loss of follow up
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01980745

Locations
Brazil
University of São Paulo School of Medicine
Sao Paulo, Brazil, 05403-010
Sponsors and Collaborators
University of Sao Paulo General Hospital
Investigators
Principal Investigator: Débora R Terrabuio, master University of São Paulo, School of Medicine.
  More Information

Publications:
Responsible Party: DÉBORA RAQUEL BENEDITA TERRABUIO, MD, University of Sao Paulo General Hospital
ClinicalTrials.gov Identifier: NCT01980745     History of Changes
Other Study ID Numbers: CAPPesq 0697/07, 0697/07
Study First Received: September 24, 2013
Last Updated: November 4, 2013
Health Authority: Brazil: Ethics Committee

Keywords provided by University of Sao Paulo General Hospital:
autoimmune hepatitis
recurrence
treatment withdrawal
chloroquine
maintenance of remission

Additional relevant MeSH terms:
Hepatitis, Autoimmune
Autoimmune Diseases
Hepatitis
Hepatitis A
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepatitis, Chronic
Immune System Diseases
Chloroquine
Chloroquine diphosphate
Amebicides
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antimalarials
Antirheumatic Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents

ClinicalTrials.gov processed this record on July 26, 2014